Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

@article{Brave2011VandetanibIB,
  title={Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.},
  author={Sandra R. Brave and Rajesh Odedra and Neil H. James and Neil R. Smith and Gayle B. Marshall and Kerry L Acheson and Dawn J Baker and Zoe Howard and Lynsay Jackson and Kirsty E Ratcliffe and Anna Wainwright and Susan Lovick and D Mark Hickinson and Robert W. Wilkinson and Simon T. Barry and Georgina Speake and Anderson Joseph AstraZeneca R D Alderley Ryan},
  journal={International journal of oncology},
  year={2011},
  volume={39 1},
  pages={271-8}
}
Vandetanib is a multi-targeted receptor tyrosine kinase inhibitor that is in clinical development for the treatment of solid tumours. This preclinical study examined the inhibition of two key signalling pathways (VEGFR-2, EGFR) at drug concentrations similar to those achieved in the clinic, and their contribution to direct and indirect antitumour effects of vandetanib. For in vitro studies, receptor phosphorylation was assessed by Western blotting and ELISA, cell proliferation was assessed… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy • 2015
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2008

Similar Papers

Loading similar papers…